Abstract 2485
Background
Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality. This study focused on identification of RNA-Seqexpressionsignature for prognosis prediction of Uterine Sarcoma.
Methods
We obtained RNA-Seqexpression profiles from The Cancer Genome Atlas (TCGA) database and differential expressed genes (DEGs) were identified between US tissues and normal tissues. Univariate Cox proportional hazards regression analysis was performed to identify Prognosis associated DEGscorrelated with survival of US patients.The RNA-Seqbased prognostic signature was identified by least absolute shrinkage and selection operator (LASSO) Cox model. The cohort was randomly divided into training and testing groups. Thebiological pathway and processof putative RNA targets was also analyzed by bioinformatics.
Results
This study identified a RNA-Seq signature based on 11 genes, AP000320.1, HNRNPA1P33, RPL21P10, AC067773.1, AC011933.3, STX19, AC091133.4, HIST1H3A, AC004988.1, AL356585.1 and HNRNPA3P1. In the training group, the median OS in the high-risk and low-risk groups were 13.7 vs 88.1 months (HR, 0.204, 95% CI, 0.08589 - 0.4846; P < 0.0001), respectively. In the testing group, the median OS in the high-risk and low-risk groups were 11.9 vs 67.2 months (HR, 0.04315, 95% CI, 0.004845 - 0.3842; P < 0.0001) respectively. Genes in the model were put into gene ontology biological process enrichment and Kyoto Encyclopedia of Genes and Genomes signaling pathways analysis, which suggested that these genes might contribute to cancer-associated processes such as the nuclear nucleosome and DNA packaging complex.
Conclusions
This 11-genebased prognostic signature may improve prognosis prediction of US.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Linguistic correction
Resources from the same session
2551 - Efficacy of dose-dense (DD) adjuvant chemotherapy (CT) in hormone receptor positive/HER2-negative early breast cancer (BC) patients (pts) according to immunohistochemically (IHC) defined luminal subtypes: an exploratory analysis of the GIM2 trial.
Presenter: Benedetta Conte
Session: Poster Display session 2
Resources:
Abstract
3426 - High dose Neo-adjuvant chemotherapy in Triple-Negative breast cancer with evidence of homologous recombination deficiency (HRD).
Presenter: Sonja Vliek
Session: Poster Display session 2
Resources:
Abstract
3792 - Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: pooled analysis of prospective neoadjuvant breast cancer (BC) trials
Presenter: Gustavo Werutsky
Session: Poster Display session 2
Resources:
Abstract
4044 - Estimating radiotherapy-induced cardiovascular mortality in female breast cancer patients.
Presenter: Mark De Ridder
Session: Poster Display session 2
Resources:
Abstract
719 - 3-year follow-up of a phase III trial comparing the efficacy and safety of neoadjuvant and adjuvant trastuzumab and its biosimilar CT-P6 in HER2 positive early breast cancer (EBC)
Presenter: Justin Stebbing
Session: Poster Display session 2
Resources:
Abstract
3595 - Adjuvant chemotherapy in elderly breast cancer patients: pattern of use and impact on overall survival
Presenter: Axel Berthelot
Session: Poster Display session 2
Resources:
Abstract
3992 - Carboplatin-containing neoadjuvant chemotherapy for triple negative breast cancer (TNBC): a propensity score-matched study.
Presenter: Maria Vittoria Dieci
Session: Poster Display session 2
Resources:
Abstract
3477 - Impact of adjuvant trastuzumab emtansine (T-DM1) on incidence of metastatic breast cancer (mBC): an epidemiological model of patients with HER2-positive breast cancer (BC) who did not achieve pathological complete response (pCR) after neoadjuvant treatment (non-pCR)
Presenter: Mellissa Williamson
Session: Poster Display session 2
Resources:
Abstract
3928 - Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study
Presenter: Hans Tesch
Session: Poster Display session 2
Resources:
Abstract
2184 - The clinical impact of adjuvant dose-dense sequential chemotherapy (dds-CT) in patients with high-risk operable breast cancer (BC); pooled analysis of 6 clinical trials.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract